As of November 10, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Ocular Therapeutix, Inc. The largest reported stake is Fmr LLC's, at 15%. 12 filings are on record since July 8, 2025 (Schedule 13G/A, November 5, 2025).
Sell to companies like Ocular Therapeutix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 14,910,631 · Shared voting: 0 · Sole dispositive: 15,227,768 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-29
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 20,850,000 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-27
- · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 6,862,972 · Sole dispositive: 0 · Shared dispositive: 6,862,972 · SCHEDULE 13G/A, 2026-02-17
- · Holder: Deep Track Capital, LP · Percent: 4.31% · SCHEDULE 13G/A
Ocular Therapeutix, Inc has 12 Schedule 13D or 13G filings on record since 2025-07-08. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15% | 31,785,634 | SCHEDULE 13G/A, 2025-11-05 | 2025-09-30 |
| Deep Track Capital, LP | 9.53% | 20,850,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 7% | 15,227,768 | SCHEDULE 13G/A, 2026-07-29 | 2026-06-30 |
| Summer Road LLC | 5.7% | 12,134,357 | SCHEDULE 13G, 2025-12-08 | 2025-12-04 |
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Ocular Therapeutix, Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Ocular Therapeutix, Inc and the records around it.
Ocular Therapeutix, Inc elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Ocular Therapeutix, Inc
Get an email when Ocular Therapeutix, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ocular Therapeutix, Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ocular Therapeutix, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ocular Therapeutix, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 0 | 0 | 0 | 20,850,000 | SCHEDULE 13G/A, 2026-05-15 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 20,850,000 | 0 | 20,850,000 | SCHEDULE 13G/A, 2026-05-15 |
| David Kroin | 0 | 20,850,000 | 0 | 20,850,000 | SCHEDULE 13G/A, 2026-05-15 |
| BlackRock, Inc. | 14,910,631 | 0 | 15,227,768 | 0 | SCHEDULE 13G/A, 2026-07-29 |
| Venrock Healthcare Capital Partners III, L.P. | 0 | 6,862,972 | 0 | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 |
| VHCP Co-Investment Holdings III, LLC | 0 | 6,862,972 | 0 | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 |
| Venrock Healthcare Capital Partners EG, L.P. | 0 | 6,862,972 | 0 | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 |
| VHCP Management III, LLC | 0 | 6,862,972 | 0 | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 |
| VHCP Management EG, LLC | 0 | 6,862,972 | 0 | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 |
| Nimish Shah | 0 | 6,862,972 | 0 | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 |
| Bong Y. Koh | 0 | 6,862,972 | 0 | 6,862,972 | SCHEDULE 13G/A, 2026-02-17 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-27 |
The latest filing identifies Ocular Therapeutix, Inc by CUSIP 67576A100 and gives its principal executive office as 14 Crosby Drive, 3rd Floor, BEDFORD, MA 01730 (SCHEDULE 13G/A, 2026-07-29).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G/A, 2026-02-17
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-08 | Fmr LLC | 12.3% | SCHEDULE 13G |
| 2025-10-17 | BlackRock, Inc. | 5.8% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 6.18% | SCHEDULE 13G/A |
| 2025-11-14 | Venrock Healthcare Capital Partners III, L.P. | 7.3% | SCHEDULE 13G/A |
| 2025-12-08 | Summer Road LLC | 5.7% | SCHEDULE 13G |
| 2026-02-10 | Deep Track Capital, LP | 4.31% | SCHEDULE 13G/A |
| 2026-02-10 | Deep Track Capital, LP | 5.13% | SCHEDULE 13G |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 3.2% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Deep Track Capital, LP | 9.53% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 7% | SCHEDULE 13G/A |
Questions about who owns Ocular Therapeutix, Inc
Who owns Ocular Therapeutix, Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Ocular Therapeutix, Inc: Fmr LLC (15%, Schedule 13G/A, filed 2025-11-05), Deep Track Capital, LP (9.53%, Schedule 13G/A, filed 2026-05-15), BlackRock, Inc. (7%, Schedule 13G/A, filed 2026-07-29) and Summer Road LLC (5.7%, Schedule 13G, filed 2025-12-08).
Who are the largest shareholders of Ocular Therapeutix, Inc?
By the share each holder's latest filing reports, the largest holders of Ocular Therapeutix, Inc on this page are Fmr LLC (15%), Deep Track Capital, LP (9.53%) and BlackRock, Inc. (7%).
When did Fmr LLC buy into Ocular Therapeutix, Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2025-07-08, reporting 12.3%; its latest, Schedule 13G/A filed 2025-11-05, reports 15%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Ocular Therapeutix, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Leadership change: Riad Sherif appointed, Director, and 1 more | — | Leadership changes | Source |
| October 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 12, 2026 | Leadership change: Jason Robins appointed, Chief Financial Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Ocular Therapeutix, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.